Myasthenie grave, traitements et remissions. [Myasthenia gravis: treatments and remissions]

Détails

ID Serval
serval:BIB_95DAE3C34524
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Myasthenie grave, traitements et remissions. [Myasthenia gravis: treatments and remissions]
Périodique
Revue Médicale Suisse
Auteur(s)
Dunand  M., Lalive  P. H., Vokatch  N., Kuntzer  T.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
05/2007
Peer-reviewed
Oui
Volume
3
Numéro
110
Pages
1185-6, 1188-90
Notes
English Abstract Journal Article Review --- Old month value: May 9
Résumé
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, due to the binding of autoantibodies to the nicotinic acetylcholine receptor (AChR), or more rarely to a muscle specific kinase (MuSK). It affects most of the time young women and old patients, with a tendency toward increasing incidence and prevalence. Clinical presentation, with fluctuating weakness of ocular, facial and bulbar muscles has a wide range of severity. Evolution is characterized by remissions and exacerbations. The goal of treatment is a complete remission, which implies a sustained collaboration between the general practitioner and the specialized centre and the use of symptomatic treatment (anticholinesterasic) in association with immunomodulators/suppressors (prednisone and azathioprine); although other treatments are available.
Mots-clé
Humans Myasthenia Gravis/*diagnosis/*drug therapy Remission Induction
Pubmed
Création de la notice
25/01/2008 13:44
Dernière modification de la notice
03/03/2018 19:41
Données d'usage